What a week. The news was good on so many fronts. The addition...

What a week. The news was good on so many fronts.
The addition of Interluken 2 was the magic sauce that gave Azer-cel wings and made short work of DLBCL. As one poster pointed out earlier in the week, we knew this was the likely outcome based on the data received from Precision and therefore it was really just confirmation. Maybe the market just sold the news. In reality we remain stuck around 5c because it’s still a year away from a registrational trial and the big news will be understanding how Azer-cel combines with OnCARlytics which is also a year away.

Maybe all the discussions with US investors has got the share price locked in this range in anticipation of the capital raise. I’m sure these US players will prefer getting set at 4c over 14c everyday of the week. It can’t be all that hard to control the price of a stock with 8 billion on issue.

An interested party looking at acquisition could easily pick up 19% from all those trying to keep a lid on it right now. That’s just wishful thinking and the volume just looks sad again so it’s back to waiting on data.

We either need a partnership deal or an asset sale or an offer for the whole business. Until then it’s like watching paint dry. This time next year. Until then, sit back and relax. Find a few good books to read.